On the heels of Take­da pact, Pep­tiDream kicks off $2.2B deal to broad­en Al­ny­lam's siR­NA de­liv­ery scope

Pep­tiDream has more tricks up its sleeve.

Days af­ter beef­ing up a CNS drug dis­cov­ery deal with Take­da to the tune of $3.5 bil­lion, the Japan­ese pep­tide spe­cial­ist re­vealed it’s scored an­oth­er pact with Al­ny­lam, fo­cused on pep­tide-siR­NA con­ju­gates. The up­front, R&D fund­ing and mile­stones add up to $2.2 bil­lion.

De­liv­ery of small in­ter­fer­ing RNA — dou­ble-strand­ed ge­net­ic ma­te­r­i­al that can “si­lence” prob­lem­at­ic genes — has long been a ma­jor chal­lenge for this class of ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER